Biogen (BIIB) Tops Q3 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Biogen (BIIB) PT Raised to $355 at Leerink Partners
October 25, 2017 7:29 AM EDTLeerink Partners raised its price target on Biogen (NASDAQ: BIIB) to $355.00 (from $351.00) while maintaining a Market Perform rating.
... MoreBiogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM EDTBiogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS). The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.
These data... More
BMO Capital Upgrades Biogen (BIIB) to Outperform
October 25, 2017 1:01 AM EDTBMO Capital upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $381.00 (from $382.00).
Analyst Ian Somaiya says the MS thesis is playing out. The analyst is not "calling the bottom on BIIB" noting the MS franchise estimate... More
SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel
October 24, 2017 11:58 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is an opportunity.
"Some SPINRAZA confusion based in flattish U.S. sales in the face of 75% patient number increase," Shrader commented. "We expect the 2Q revenue... More
